PC c.418_420delinsAGC ;(p.G140S)

Variant ID: 11-66638853-CCC-GCT

NM_001040716.1(PC):c.418_420delinsAGC;(p.G140S)

This variant was identified in 6 publications

View GRCh38 version.




Publications:


Dolutegravir: An Integrase Strand Transfer Inhibitor for the Treatment of Human Immunodeficiency Virus 1 in Adults.

The Journal Of Pharmacy Technology : Jpt : Official Publication Of The Association Of Pharmacy Technicians
Mercadel, Candice J CJ; Skelley, Jessica W JW; Kyle, Jeffrey A JA; Elmore, Lindsey K LK
Publication Date: 2014-12

Variant appearance in text: PC: G140S
PubMed Link: 34860879
Variant Present in the following documents:
  • Main text
View BVdb publication page



Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.

Plos One
You, Jiangzhou J; Wang, Hongren H; Huang, Xiaojun X; Qin, Zhen Z; Deng, Zhaomin Z; Luo, Jun J; Wang, Baoning B; Li, Mingyuan M
Publication Date: 2016

Variant appearance in text: PC: G140S
PubMed Link: 27532886
Variant Present in the following documents:
  • pone.0160087.pdf
View BVdb publication page



Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy.

Plos One
Li, Jonathan Z JZ; Chapman, Brad B; Charlebois, Patrick P; Hofmann, Oliver O; Weiner, Brian B; Porter, Alyssa J AJ; Samuel, Reshmi R; Vardhanabhuti, Saran S; Zheng, Lu L; Eron, Joseph J; Taiwo, Babafemi B; Zody, Michael C MC; Henn, Matthew R MR; Kuritzkes, Daniel R DR; Hide, Winston W; , ; Wilson, Cara C CC; Berzins, Baiba I BI; Acosta, Edward P EP; Bastow, Barbara B; Kim, Peter S PS; Read, Sarah W SW; Janik, Jennifer J; Meres, Debra S DS; Lederman, Michael M MM; Mong-Kryspin, Lori L; Shaw, Karl E KE; Zimmerman, Louis G LG; Leavitt, Randi R; De La Rosa, Guy G; Jennings, Amy A
Publication Date: 2014

Variant appearance in text: PC: G140S
PubMed Link: 24603872
Variant Present in the following documents:
  • Main text
  • pone.0090485.pdf
View BVdb publication page



Unprocessed viral DNA could be the primary target of the HIV-1 integrase inhibitor raltegravir.

Plos One
Ammar, Farah F FF; Abdel-Azeim, Safwat S; Zargarian, Loussinée L; Hobaika, Zeina Z; Maroun, Richard G RG; Fermandjian, Serge S
Publication Date: 2012

Variant appearance in text: PC: G140S
PubMed Link: 22768342
Variant Present in the following documents:
  • pone.0040223.pdf
View BVdb publication page



Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A.

Antimicrobial Agents And Chemotherapy
Reigadas, S S; Masquelier, B B; Calmels, C C; Laguerre, M M; Lazaro, E E; Vandenhende, M M; Neau, D D; Fleury, H H; Andréola, M L ML
Publication Date: 2011-07

Variant appearance in text: PC: G140S
PubMed Link: 21576445
Variant Present in the following documents:
  • Main text
View BVdb publication page



Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.

Antimicrobial Agents And Chemotherapy
Delelis, Olivier O; Thierry, Sylvain S; Subra, Frédéric F; Simon, Françoise F; Malet, Isabelle I; Alloui, Chakib C; Sayon, Sophie S; Calvez, Vincent V; Deprez, Eric E; Marcelin, Anne-Geneviève AG; Tchertanov, Luba L; Mouscadet, Jean-François JF
Publication Date: 2010-01

Variant appearance in text: PC: G140S
PubMed Link: 19901095
Variant Present in the following documents:
  • Main text
View BVdb publication page